Literature DB >> 2329274

An absence of T cells in murine bone marrow allografts leads to an increased susceptibility to rejection by natural killer cells and T cells.

W J Murphy1, V Kumar, J C Cope, M Bennett.   

Abstract

The mechanisms behind the increased incidence of marrow graft failure in recipients that receive allogeneic marrow depleted of T cells were studied. Recipient mice were lethally irradiated and challenged with bone marrow cells (BMC) from C.B-17 +/+ (+/+) donors. Radioisotope 125IUdR incorporation was assessed 5 to 7 days after transfer to determine the extent of engraftment. Some groups received BMC in which the T cells were removed by treatment with antibody and C. In addition, some groups received BMC from T cell-deficient C.B-17 scid/scid (SCID) mice to determine the postulated need for donor T cells in hematopoiesis and engraftment. In a model system that distinguishes between possible host NK cell and radioresistant T cell-mediated rejection of marrow allografts, it was determined that the absence of donor T cells in a marrow graft does not affect engraftment in syngeneic recipients. However, both host NK cell and radioresistant T cell rejection was markedly enhanced when SCID BMC or BMC from C.B-17 +/+ donors that had T cells removed by antibody and complement were infused into irradiated allogeneic recipients. Furthermore, the addition of alloreactive thymocytes as a source of T cells could abrogate this increased susceptibility of the BMC to host rejection mechanisms. As determined by histology and 59Fe uptake, the addition of thymocytes resulted in enhanced erythropoiesis. These results suggest that the increased incidence of marrow graft failure when BMC depleted of T cells are used is a result of active rejection by host effector cells and that the adverse effect of marrow T cell depletion can be reversed by the addition of thymocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2329274

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells.

Authors:  Isabel Barao; Alan M Hanash; William Hallett; Lisbeth A Welniak; Kai Sun; Doug Redelman; Bruce R Blazar; Robert B Levy; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

2.  Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing.

Authors:  Kai Sun; Maite Alvarez; Erik Ames; Isabel Barao; Mingyi Chen; Dan L Longo; Doug Redelman; William J Murphy
Journal:  Blood       Date:  2011-12-19       Impact factor: 22.113

3.  Induction of cutaneous graft-versus-host disease by local injection of unprimed T cells.

Authors:  K Kawai; Y Matsumoto; H Watanabe; M Ito; M Fujiwara
Journal:  Clin Exp Immunol       Date:  1991-05       Impact factor: 4.330

4.  Gammadelta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection.

Authors:  Sanja Vodanovic-Jankovic; William R Drobyski
Journal:  Biol Blood Marrow Transplant       Date:  2006-11       Impact factor: 5.742

Review 5.  In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice.

Authors:  T S Barry; B F Haynes
Journal:  J Clin Immunol       Date:  1992-09       Impact factor: 8.317

6.  Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.

Authors:  P J Martin
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

7.  Successful engraftment of human postnatal thymus in severe combined immune deficient (SCID) mice: differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens.

Authors:  T S Barry; D M Jones; C B Richter; B F Haynes
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.